Regenerative Medicine: Injectable Cell-Based Therapeutics and Approved Products

被引:13
|
作者
Golchin, Ali [1 ]
Shams, Forough [2 ]
Kangari, Parisa [3 ]
Azari, Arezoo [4 ]
Hosseinzadeh, Simzar [4 ]
机构
[1] Shahid Beheshti Univ Med Sci, Sch Adv Technol Med, Dept Tissue Engn & Appl Cell Sci, Student Res Comm, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Sch Adv Technol Med, Dept Biotechnol, Tehran, Iran
[3] Shiraz Univ Med Sci, Sch Adv Technol Med, Dept Tissue Engn & Appl Cell Sci, Shiraz, Iran
[4] Shahid Beheshti Univ Med Sci, Sch Adv Technol Med, Dept Tissue Engn & Appl Cell Sci, Tehran, Iran
来源
CELL BIOLOGY AND TRANSLATIONAL MEDICINE, VOL 7: STEM CELLS AND THERAPY: EMERGING APPROACHES | 2020年 / 1237卷
关键词
Cellular therapy; Injectable product; Regenerative medicine; MESENCHYMAL STEM-CELLS; CHIMERIC ANTIGEN RECEPTOR; DELIVERY; THERAPY; MIGRATION; HYDROGELS;
D O I
10.1007/5584_2019_412
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Cellular-based therapies have drawn a great deal of attention thanks to their regenerative medicine approaches to treat incurable diseases and specific injuries. In this regard, injectable cell delivery systems could actualize the therapeutically beneficial outcomes of cell-based therapeutic products. These systems have found considerable clinical uses. Hence, the recent studies have focused on developing injectable bio-constructs to protect transplanted cells during delivery and stimulating endogenous regeneration through interactions of these cells and host tissue. This paper introduces a framework, as a general concept, to improve cell delivery systems for cell-based therapeutic products. Studies on stable injectable carriers can enhance cell homing, proliferation, viability, dressing of irregular shape of target sites, and subsequently support transplanted cell functionality. However, more studies should be conducted on new technologies for the injectable cell-based product for cell delivery and the clinical applications.
引用
收藏
页码:75 / 95
页数:21
相关论文
共 50 条
  • [1] An FDA perspective on preclinical development of cell-based regenerative medicine products
    Alexander M Bailey
    Michael Mendicino
    Patrick Au
    Nature Biotechnology, 2014, 32 : 721 - 723
  • [2] An FDA perspective on preclinical development of cell-based regenerative medicine products
    Bailey, Alexander M.
    Mendicino, Michael
    Au, Patrick
    NATURE BIOTECHNOLOGY, 2014, 32 (08) : 721 - 723
  • [3] Fluorescent cell-based reference standards for quality assessment of regenerative medicine products
    Rahman, S.
    Baradez, M. O.
    Marshall, D.
    JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE, 2012, 6 : 374 - 374
  • [4] Cell-based therapy in lung regenerative medicine
    Yang, Jibing
    Jia, Zhenquan
    REGENERATIVE MEDICINE RESEARCH, 2014, 2
  • [5] Cell-based therapies for skeletal regenerative medicine
    Kwan, Matthew D.
    Slater, Bethany J.
    Wan, Derrick C.
    Longaker, Michael T.
    HUMAN MOLECULAR GENETICS, 2008, 17 : R93 - R98
  • [6] Cell-based regenerative medicine for renovascular disease
    Lerman, Lilach O.
    TRENDS IN MOLECULAR MEDICINE, 2021, 27 (09) : 882 - 894
  • [7] Cell-Based Therapeutics: The Next Pillar of Medicine
    Fischbach, Michael A.
    Bluestone, Jeffrey A.
    Lim, Wendell A.
    SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (179)
  • [8] Safety of Cell Therapeutics/Cell-based medicinal products (CBMP)
    Scherer, Juergen
    Seitz, Rainer
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2015, 58 (11-12) : 1199 - 1200
  • [9] Regulating cell-based regenerative medicine: the challenges ahead
    Ali, Robin R.
    Hollander, Anthony P.
    Kemp, Paul
    Webster, Andrew
    Wilkins, Martin R.
    REGENERATIVE MEDICINE, 2014, 9 (01) : 81 - 87
  • [10] Stem Cell-Based Tissue Engineering for Regenerative Medicine
    Shi, Donglu
    Tatu, Rigwed
    Liu, Qing
    Hosseinkhani, Hossein
    NANO LIFE, 2014, 4 (02)